Human Oncology & Pathogenesis Program

The Ping Chi Lab

Research

Ping Chi
Ping Chi, MD, PhD
Co-Director, Sarcoma Translational Research, MSK Sarcoma Center

It is well recognized that the cellular context contributes to susceptibility to oncogenic transformation mediated by different “driver” oncogenes. The focus of our laboratory is to discover and understand the critical genetic and epigenetic factors that determine the cellular-context-dependent oncogenesis in distinct cancer types, with a primary focus on sarcoma and melanoma. We use multimodality approaches, including  transcriptome analyses, epigenome mapping, and gene-expression-based high-throughput screens, as well as murine models to understand the mechanisms of pathogenesis and to develop biomarkers and targeted therapies based on insight into disease pathogenesis.

View Lab Overview

Chi-Chen Lab

Featured News

Event
Graduates and speakers pose on a stage
2017 MSK Convocation and Commencement Ceremony Celebrates Distinguished Scientists and Young Scholars
Degrees were presented and awards were given at the 38th annual ceremony held on May 18.
In the Lab
Pictured: Ping Chi
Molecular Studies Provide New Clues about Rare Soft Tissue Sarcoma
Genetic analysis reveals biomarkers and possible drug targets for malignant peripheral nerve sheath tumors.
Announcement
Pictured: 2012 Rock Stars of Science
Geoffrey Beene Rock Stars of Science™ Campaign Features Memorial Sloan Kettering Researchers
The initiative, focused on investigators from Memorial Sloan Kettering’s Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research.

View All Featured News

Publications Highlights

Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Roman MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G, Fishinevich E, Meng Y, Wong EWP, Yan J, Giff E, Pappalardi MB, McCabe MT, Fletcher JA, Rudin CM, Chandarlapaty S, Scandura JM, Koche RP, Glass JL, Antonescu CR, Zheng D, Chen Y*, Chi P*. PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry. Cancer Discovery. 2022 Jul 5:cd.21.1671. doi: 10.1158/2159-8290.CD-21-1671. Online ahead of print. PMID: 35789380; Featured in “In the Spotlight”.

Yan J, Chen Y, Patel AJ, Warda S, Lee CJ, Nixon BG, Wong EWP, Miranda-Román MA, Yang N, Wang Y, Pachai MR, Sher J, Giff E, Tang F, Khurana E, Singer S, Liu Y, Galbo PM Jr, Maag JL, Koche RP, Zheng D, Antonescu C, Deng L, Li M, Chen Y*, Chi P*. Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic therapeutic viruses. Journal of Clinical Investigation. 2022 Jul 19:e153437. doi: 10.1172/JCI153437. Epub ahead of print. PMID: 35852856.

Chi P*, Qin LX, Nguyen B, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 2022;40(9):997-1008. PMCID: PMC8937014.

Chi P*, Qin LX, Camacho N, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Francis JH, Martindale M, Phelan HT, Biniakewitz MD, Lee CJ, Singer S, Hwang S, Berger MF, Chen Y, Antonescu CR, Tap WD*. Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research. 2022;28(8):1507-1517. PMCID: PMC9012681.

Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K, Bareja R, Han T, Liu EM, Palladino A, Di W, Gao D, Abida W, Beg S, Puca L, Meneses M, de Stanchina E, Berger MF, Gopalan A, Dow LE, Mosquera JM, Beltran H, Sternberg CN, Chi P, Scher HI, Sboner A, Chen Y, Khurana E. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022; 376(6596):eabe1505. PMCID: PMC9299269.

View All Publications

People

Ping Chi

Ping Chi, MD, PhD

Co-Director, Sarcoma Translational Research, MSK Sarcoma Center

  • Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.
  • MD, Weill Cornell Medical College
  • PhD, The Rockefeller University
View physician profile
Physician profile

Members

Yudi Bao
Research Associate
Woo Hyun (Alex) Cho
Research Technician
Zoe Jacobs
Research Technician
Kyle Kristoff
Research Technician
Marion Liu
Assistant Attending, Surgery
Sarah Qadir
Laboratory Administrator
Alina Teuber
Research Scholar
Elissa Wai Wong Pung
Elissa Wai Pung Wong
Scientific Research Lead
Juan Yan
Senior Research Scientist
Yang Zeng
Research Scholar
Yang Zeng
Research Scholar
Tao Zhang
Tao Zhang
Research Associate
Jiasheng Zhou
Data Analyst
Yuanyuan Xie
Yuanyuan Xie
Research Fellow
Yuedan Chen
Yuedan Chen
Graduate Research Assistant
Gabriella Bayshtok
Research Technician
Vaishnavi Reeya Callychurn
Vaishnavi Reeya Callychurn
Research Technician
Cindy Lee
Cindy Lee
Research Assistant
Dan Li, Research Fellow
Dan Li
Research Fellow
Miguel Miranda-Roman
Miguel A. Miranda-Roman
Postdoctoral Fellow at Boehringer Ingelheim in Ridgefield, CT
Devan Murphy
Devan Murphy
Research Technician
Mohini Pachai
Mohini Pachai
Research Technician
Shraddha Pancholi
Shraddha Pancholi
Research Secretary
Amish Patel
Amish Patel
Research Associate
Jessica Sher
Jessica Sher
Research Technician
Inna Sirota
Inna Sirota
Research Technician
Sewit Teckie
Sewit Teckie
Radiation Oncology Resident
Fanny Tomas
Research Fellow
Edward Walczak
Edward Walczak
Research Technician
Thomas Wiesner
Thomas Wiesner
Research Fellow
Qifan Zhang
Qifan Zhang
Research Technician

Achievements

  • Kimmel Scholar Award, Sidney Kimmel Foundation (2012)
  • Research Grant, Sarcoma Foundation of America (2012)
  • Grant, GIST Cancer Awareness Foundation (2012)
  • Director’s New Innovator Award, National Institutes of Health (2012)
  • Clinical Scientist Development Award, National Instistutes of Health (2011)

Lab News & Events

Upcoming event

Transposable Elements and Cancer Epigenome Evolution

Memorial Sloan Kettering Cancer Center
Rockefeller Research Laboratories
430 East 67th Street
Room RRL-116
New York, NY 10065

Zoom

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Ping Chi discloses the following relationships and financial interests:

  • Boxer Capital, LLC
    Professional Services and Activities
  • Chinese Institutes for Medical Research (CIMR)
    Professional Services and Activities (Uncompensated)
  • Deciphera
    Professional Services and Activities
  • Ningbo NewBay Medical Technology Co., Ltd.
    Professional Services and Activities
  • Peking University
    Professional Services and Activities
  • Peking University People's Hospital
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures

Related topics: